Objective: Analysis of the effectiveness of vitamin D in patients with PD depending on clinical manifestations and concentration levels of 25 (OH) D.
Background: Recent studies have shown that low levels of vitamin D are more common in patients with PD compared with healthy individuals, and low levels of vitamin D in serum can be a prognostic factor for the risk and severity of PD.
Method: Patients with PD were divided into two groups. The main group consisted of patients who received treatment according to the standards of diagnosis and treatment approved by the Ministry of Health of the Republic of Uzbekistan (n = 30). The 2nd group consisted of patients receiving vitamin D along with standard therapy (n = 30). The recommended drug for treating vitamin D deficiency is colacalciferol (D3), in the dose of 7000 IU per day orally for 8 weeks for Vitamin D deficiency and 4 weeks per day for 4 weeks for D insufficiency.
Results: Patients of the two groups were comparable in terms of gender, age, disease duration, 25 (OH) D level, disease severity, and cognitive function. The average age in the main group was 66.3 ± 10.3, in the group receiving D3 61.2 ± 9.6 (table 1)
The results show that both groups show significant improvements. Moreover, the Pearson coefficient shows a positive and significant relationship with the concentration of 25 (OH) D and cognitive functions of PD. Patients receiving vitamin D group, the concentration of 25 (OH) D increased from 22.3 ± 7.3 to 35.8 ± 6.1 (p <0.0001) at 16 weeks. The stages according to H&Y remained statistically insignificant (p> 0.05). The quality of life shows that, after applying vitamin D for 16 weeks, it statistically significantly improved from 16.7 ± 5.1 to 13.6 ± 3.4.
According to our results, after treatment with vitamin D, patients with PD show a positive and significant relationship with the concentration of 25 (OH) D and clinical manifestations, particularly, cognitive functions and quality of life of PD.
Conclusion: The inclusion of 7000ME colacalciferol D3 in the standard PD treatment protocol for 8 weeks with D-deficiency and 4 weeks with D-insufficiency can significantly improve the cognitive functions and quality of life of patients.
To cite this abstract in AMA style:
N.A Mansurova, Y.N Madjidova. Vitamin D assessment in patents with Parkinson’s disease [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/vitamin-d-assessment-in-patents-with-parkinsons-disease/. Accessed May 16, 2025.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/vitamin-d-assessment-in-patents-with-parkinsons-disease/